In an interview with The Center for Biosimilars®, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, discussed the letter recently sent to HHS addressing physician concerns with proposed legislation.
Last week, 9 physician groups sent a joint letter to HHS Secretary Alex Azar to voice concerns about the president’s 2019 budget and the Council of Economic Advisers’ drug plan.
When asked what the burden on the patient would be if practitioners have to stop prescribing biologic therapies altogether due to concerns outlined in the letter, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, told the Center for Biosimilars® in an email that patients losing access to biologic therapy can be a crisis.
“Most people currently taking a biologic have spent years obtaining a diagnosis, then trying initial treatment with pills or other drugs, which may have been inadequate or caused side effects, and now if they’re doing well, stopping biologic treatment is likely to cause a flare of disease… so, once a person’s disease is well-controlled with biologic therapy, that treatment shouldn’t be stopped for nonmedical reasons,” Worthing wrote.
Proposed legislation, such as President Donald Trump’s budget, could impact patients starting to use biosimilars, he added. “Reducing access to biosimilars at this time could possibly threaten to reduce demand for biosimilars and prevent their reason for being, which is to reduce biologic drug prices. This would be an unfortunate unintended consequence of a plan geared toward reducing biologic drug prices,” said Worthing.
In the letter, the groups also urged HHS to repeal the sequester cuts to Medicare Part B reimbursements. When asked what he has personally seen happen in his own practice due to the sequester cuts, Worthing noted, “The large group practice in which I practice has leveraged efficiencies in order to continue to provide Part B drug services to Medicare beneficiaries despite the sequester’s nearly 30% reimbursement cut; however, doctors in small or underserved communities have had to stop providing these drugs because of the razor-thin margins that threaten viability. Their patients have been forced to different sites of service like hospitals, which can cost the system more money or can sometimes be inconvenient or unfamiliar to patients.”
Finally, Worthing commended the White House for prioritizing the reduction of high drug prices. “The ACR and other stakeholders stand ready to work with the administration to do just that; however, we want to make sure proposals don’t have the unintended consequence of reducing access to these critical treatments for our patients.”
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.